SOLASCURE Ltd (SolasCure), a biotechnology company developing a novel treatment to transform chronic wound healing, today ...

Now in its third year, the trial is led by The Wistar Institute in collaboration with INOVIO, AstraZeneca, and clinical investigators at the University of Pennsylvania. It is funded by the Coronavirus ...

Sensorion Announces the End of Patient Inclusion in NOTOXIS Phase 2a Clinical Trial of SENS-401 for the Prevention of Cisplatin-Induced Ototoxicity ...

UK biotechnology company SolasCure has commenced the randomised, controlled CLEANVLU2 Phase II trial of Aurase Wound Gel for chronic wound treatment, with the first subject enrolled. The patented ...

today announced new safety and immunogenicity data from ongoing analyses of results from the Company’s first Phase 1 proof-of-concept clinical trial of IMNN-101, its investigational DNA plasmid ...

(RTTNews) - INOVIO (INO) announced promising interim results from an ongoing Phase 1 proof-of-concept ... trial is being led by The Wistar Institute in collaboration with INOVIO, AstraZeneca, and ...

today announced the enrollment of the last patient in its NOTOXIS Proof of Concept (POC) Phase 2a clinical trial of SENS-401 for the prevention of Cisplatin-Induced Ototoxicity (CIO). The NOTOXIS ...

Oragenics (OGEN) announced the submission of its Investigator’s Brochure application in preparation for its Phase II clinical trial using ...

Montpellier, France Monday, March 10, 2025, 15:00 Hrs [IST] ...